Beyond MariTide, Amgen has a rich pipeline with more than 30 phase 3 programs. Some are for existing medicines seeking label expansions, such as Lumakras and Amjevita, a rheumatoid arthritis medicine.
Some results have been hidden because they may be inaccessible to you